Effects of Snuff and/or Red Wine om Metabolic Rate
Metabolic Effects of Snuff and Red Wine
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Sverige
-
Linköping, Sverige, Sweden, 60580
- Recruiting
- Faculty of Medicine and Health Sciences
-
Contact:
- Fredrik Nyström, MD
- Phone Number: +132237749
- Email: fredrik.nystrom@regionostergotland.se
-
Principal Investigator:
- Fredrik H Nystrom, professor
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria: No significant disease -
Exclusion Criteria: known illnesses, thyroid disease, need to take prednisolone, psychiatric disease,inability to understand Swedish
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: red wine and snuff
regular red wine and moist snuff
|
Two by two factorial of wine and snuff with meals
|
|
Active Comparator: red wine and nicotine-free snuff
regular red wine and nicotine-free snuff
|
Two by two factorial of wine and snuff with meals
|
|
Active Comparator: non alcoholic red wine and regular moist snuff
non alcoholic red wine and regular moist snuff with nicotine
|
Two by two factorial of wine and snuff with meals
|
|
Placebo Comparator: non-alcoholic red wine and nicotine-free snuff
Non-alcoholic red wine and nicotine-free snuff
|
Two by two factorial of wine and snuff with meals
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
level of metabolic rate
Time Frame: 4 hours
|
Measurement of metabolic rate by registration of CO2 in breath and the oxygen uptake
|
4 hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
sense of appetite
Time Frame: 4 hours
|
determination of the hormones ghrelin and GLP-1 in serum
|
4 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Hyperinsulinism
- Insulin Resistance
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Cholinergic Agents
- Ganglionic Stimulants
- Nicotinic Agonists
- Cholinergic Agonists
- Nicotine
Other Study ID Numbers
Other Study ID Numbers
- EPN2020-00839
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Insulin Sensitivity
-
NCT06766617CompletedInsulin Sensitivity/Resistance
-
NCT06772857Active, not recruitingInsulin Sensitivity/Resistance
-
NCT04482374RecruitingEndothelial Dysfunction | Vascular Stiffness | Insulin Sensitivity/Resistance | Transgenderism
-
NCT02745613CompletedInsulin Sensitivity/Resistance
-
NCT07109245RecruitingCognition | Healthy Controls | Brain Insulin Sensitivity
-
NCT01521806UnknownFocus of the Study is Insulin Sensitivity
-
NCT02524457UnknownInsulin Sensitivity and Lipid Metabolism
-
NCT01648478Completed
-
NCT04700241CompletedVascular Function | Nitrate | Brain Insulin-sensitivity
Clinical Trials on Wine with or without alcohol and snuff with or without nicotine
-
NCT04453943UnknownSpinal Cord Injuries | Paraplegia, Spinal | Paraplegia, Incomplete
-
NCT02552732TerminatedChronic Obstructive Pulmonary Disease | COPD
-
NCT02361632CompletedRespiratory Aspiration of Gastric Content
-
NCT06019910RecruitingObesity | Dyslipidemias | Blood Pressure | Dysglycemia
-
NCT03666741Active, not recruitingAortic Valve Stenosis
-
NCT02364063CompletedDaytime Urinary Incontinence
-
NCT00980941CompletedDiabetes Prevention | Obesity Prevention
-
NCT01282450CompletedNon-small Cell Lung Cancer | Stage IV (Oligo-metastases)
-
NCT00205543CompletedObstructive Sleep Apnea
-
NCT06962072RecruitingSoft Tissue Sarcoma